Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain

The cost of treating Clostridium difficile infection (CDI) in Spain is substantial. Findings from the randomised, controlled, open-label, phase 3b/4 EXTEND study showed that an extended-pulsed fidaxomicin (EPFX) regimen was associated with improved sustained clinical cure and reduced recurrence of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Terrés, Carlos, Aguado, José María, Almirante, Benito, Cobo, Javier, Grau, Santiago, Salavert, Miguel, González Antona Sánchez, Elena, López Gutiérrez, Cristina, Rubio-Rodríguez, Darío
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520320/
https://www.ncbi.nlm.nih.gov/pubmed/30989419
http://dx.doi.org/10.1007/s10096-019-03503-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520320/
https://www.ncbi.nlm.nih.gov/pubmed/30989419
http://dx.doi.org/10.1007/s10096-019-03503-4

Ejemplares similares